Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine

[1]  Jianjun Liu,et al.  A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia , 2014, Nature Genetics.

[2]  E. Dolgin.  Massive schizophrenia genomics study offers new drug directions , 2014, Nature Reviews Drug Discovery.

[3]  S. Tsai,et al.  Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. , 2014, JAMA.

[4]  T. Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing: 2014 Update , 2014, Clinical pharmacology and therapeutics.

[5]  L. Gong,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens , 2014, Clinical pharmacology and therapy.

[6]  J. Mega,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update , 2013, Clinical pharmacology and therapeutics.

[7]  James McCluskey,et al.  Human leukocyte antigen-associated drug hypersensitivity. , 2013, Current opinion in immunology.

[8]  J. Kelsoe,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Carbamazepine Dosing , 2012, Clinical pharmacology and therapeutics.

[9]  C. Sotozono,et al.  A whole-genome association study of major determinants for allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients , 2011, The Pharmacogenomics Journal.

[10]  Jacques Fellay,et al.  ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C , 2010, Nature.